| Literature DB >> 32228612 |
Qing Liu1,2,3,4, Chaogang Yang1,2,3,4, Shuyi Wang1,2,3,4, Dongdong Shi1,2,3,4, Chen Wei1,2,3,4, Jialin Song1,2,3,4, Xiaobin Lin1,2,3,4, Rongzhang Dou1,2,3,4, Jian Bai1,2,3,4, Zhenxian Xiang1,2,3,4, Sihao Huang1,2,3,4, Keshu Liu1,2,3,4, Bin Xiong5,6,7,8.
Abstract
BACKGROUND: Tumor-associated macrophages (TAMs) in the tumor microenvironment influence tumor initiation, invasion and metastasis. Several studies have shown that Wnt5a is mainly expressed in the tumor stroma, especially in TAMs. However, whether Wnt5a regulates the polarization and biological function of TAMs in colorectal cancer (CRC) is incompletely understood.Entities:
Keywords: Colorectal cancer; IL-10; M2 polarization; Tumor-associated macrophages; Wnt5a
Mesh:
Substances:
Year: 2020 PMID: 32228612 PMCID: PMC7106599 DOI: 10.1186/s12964-020-00557-2
Source DB: PubMed Journal: Cell Commun Signal ISSN: 1478-811X Impact factor: 5.712
Fig. 1The ratio of Wnt5a+CD68+/CD68+ TAMs is correlated with poor prognosis in CRC patients. a Representative immunofluorescence staining images for Wnt5a (green), CD68 (red), DAPI (blue) in CRC samples. Bar = 100 μm. b Wnt5a+CD68+/CD68+ TAMs ratio was significantly elevated in primary human CRC tissues compared with normal colorectal tissues. Statistical analysis was conducted using one-way ANOVA. c, d Association of Wnt5a+CD68+/CD68+ TAMs ratio with recurrence-free survival and overall survival of CRC patients. e Representative immunofluorescence staining images for Wnt5a (green), CD68 (red), DAPI (blue) at tumor invasive front. Bar = 100 μm. f Wnt5a+CD68+/CD68+ TAMs ratio at tumor invasive front and tumor nest in 10 CRC samples. g Representative immunofluorescence photographs for co-localization staining of Wnt5a, M2 maker (CD163) and M1 maker (HLA-DR). Bar = 100 μm. Error bars, SEM. ***P < 0.001
Correlation between the ratio of Wnt5a+CD68+/CD68+ macrophages and clinicopathologic parameters (n = 63)
| Parameters | n (%) | Wnt5a+CD68+/CD68+ ratio (n) | |||
|---|---|---|---|---|---|
| Low ( | High ( | ||||
| Gender | 0.024 | 0.877 | |||
| Male | 38 (60.32) | 19 | 19 | ||
| Female | 25 (39.68) | 13 | 12 | ||
| Age (years) | 1.905 | 0.167 | |||
| <60 | 29 (46.03) | 12 | 17 | ||
| ≥ 60 | 34 (53.97) | 20 | 14 | ||
| Tumor site | 0.013 | 0.910 | |||
| Colon | 35 (55.56) | 18 | 17 | ||
| Rectum | 28 (44.44) | 14 | 14 | ||
| Tumor size (cm) | 0.386 | 0.535 | |||
| <5 | 41 (65.08) | 22 | 19 | ||
| ≥ 5 | 22 (34.92) | 10 | 12 | ||
| Tumor grade | 1.932 | 0.165 | |||
| Poor | 38 (60.32) | 22 | 16 | ||
| Moderate/Well | 25 (39.68) | 10 | 15 | ||
| LVI | 5.773 | ||||
| Absence | 30 (47.62) | 20 | 10 | ||
| Presence | 33 (52.38) | 12 | 21 | ||
| PNI | 1.905 | 0.167 | |||
| Absence | 34 (53.97) | 20 | 14 | ||
| Presence | 29 (46.03) | 12 | 17 | ||
| TI | 6.719 | ||||
| T1–2 | 15 (23.81) | 12 | 3 | ||
| T3–4 | 48 (76.19) | 20 | 28 | ||
| LNM | 7.014 | ||||
| N0–1 | 31 (49.21) | 21 | 10 | ||
| N2–3 | 32 (50.79) | 11 | 21 | ||
| TNM stage# | 9.908 | ||||
| I/II | 33 (52.38) | 23 | 10 | ||
| III | 30 (47.62) | 9 | 21 | ||
| CEA (ng/ml) | 0.128 | 0.721 | |||
| <5 | 44 (69.84) | 23 | 21 | ||
| ≥ 5 | 19 (30.16) | 9 | 10 | ||
Notes: Bold indicates P < 0.05; #The 7th edition of the AJCC Cancer Staging Manual. Abbreviations: LVI Lymphovascular invasion; PNI Perineural invasion; TI, tumor invasion; LNM Lymph node metastasis; TNM Tumor-node-metastasis; CEA carcinoembryonic antigen; CD68 Cluster of differentiation 68; Wnt5a Wingless-type MMTV integration site family, member 5a
Univariate and multivariate analyses of clinicopathologic parameters associated with recurrence-free survival and overall survival
| Parameters | Recurrence-free survival | Overall survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |||||
| Gender (Male vs. Female) | 0.782 | 0.391–1.564 | 0.488 | 0.67 | 0.321–1.400 | 0.287 | ||||||
| Age (≥60 years vs. <60 years) | 0.639 | 0.325–1.255 | 0.194 | 0.641 | 0.316–1.303 | 0.219 | ||||||
| Tumor site (Colon vs. Rectum) | 1.015 | 0.515–2.001 | 0.965 | 1.418 | 0.700–2.876 | 0.332 | ||||||
| Tumor size (<5 cm vs. ≥ 5 cm) | 1.255 | 0.627–2.512 | 0.521 | 1.474 | 0.721–3.016 | 0.288 | ||||||
| Tumor grade (Well vs Moderate vs Poor) | 1.755 | 0.894–3.446 | 0.102 | 1.263 | 0.623–2.564 | 0.517 | ||||||
| LVI (Absence vs. Presence) | 1.998 | 0.937–4.257 | 0.073 | |||||||||
| PI (Absence vs. Presence) | 1.557 | 0.793–3.059 | 0.198 | 1.955 | 0.957–3.997 | 0.066 | ||||||
| TI (T1–2 vs. T3–4) | 1.335 | 0.686–2.597 | 0.394 | 1.104 | 0.562–2.168 | 0.774 | ||||||
| LNM (N0–1 vs. N2–3) | 0.648 | 0.366–1.147 | 0.136 | 0.630 | 0.348–1.139 | 0.126 | ||||||
| TNM stage# (I vs. II vs. III) | ||||||||||||
| CEA (≥ 5 ng/ml vs. <5 ng/ml) | 0.791 | 0.377–1.657 | 0.533 | 0.529 | 0.227–1.231 | 0.14 | ||||||
| CD68+ macrophage (Low vs. High) | 1.785 | 0.901–3.537 | 0.097 | 1.465 | 0.722–2.975 | 0.29 | ||||||
| Wnt5a+CD68+ macrophage (Low vs. High) | 0.981 | 0.441–2.182 | 0.962 | 0.925 | 0.404–2.115 | 0.853 | ||||||
| Wnt5a+CD68+/CD68+ macrophage (Low vs. High) | ||||||||||||
Notes: Bold indicates P < 0.05; #The 7th edition of the AJCC Cancer Staging Manual. Abbreviations: LVI Lymphovascular invasion; PNI Perineural invasion; TI Tumor invasion; LNM Lymph node metastasis; TNM, tumor-node-metastasis; CEA Carcinoembryonic antigen; CD68 Cluster of differentiation 68; Wnt5a Wingless-type MMTV integration site family, member 5a
Fig. 2Wnt5a is mainly expressed in M2-like TAMs. a Flow chart of generating TAMs. b Relative expression of M1 markers (HLA-DR, IL-12), M2 markers (Arg-1, CD163, CD206, IL-10, TGFβ, CCL17, CCL18, CCL22) in M0 macrophages, M2 macrophages and TAMs co-cultured with HCT116 or DLD-1 for 48 h. Error bars, SEM. c Flow cytometry analysis of the proportion of M2 cells in different groups of macrophages. Error bars, SEM. d The expression level of Wnt5a in M0, M1, M2 macrophages and TAMs co-cultured with HCT116 or DLD-1 for 48 h. e ELISA analysis of Wnt5a secretion level in macrophages, CRC cell lines and CRC cell lines co-cultured with macrophages. Error bars, SEM. f Representative immunofluorescence photographs for Wnt5a, CD163 and DAPI in different groups of macrophages. Bar = 50 μm. All experiments were performed independently at least three times. Statistical analysis was conducted using one-way ANOVA. *P < 0.05. **P < 0.01. ***P < 0.001
Fig. 3Wnt5a induces M2 macrophages polarization via IL-10. a RT-qPCR analysis of the relative expression levels of M1 markers (HLA-DR, IL-12) and M2 markers (CD163, IL-10) in M0 macrophages treated with Wnt5a. b Flow cytometry analysis showed M2 polarization (CD163+) in M0 macrophages treated with Wnt5a. This M2 polarization was reversed by Box 5 (Wnt5a inhibitor). c RT-qPCR analysis of M2 polarization-associated cytokines expression in M0 macrophages with Wnt5a treatment. d Western blot analyzed the protein expression of IL-10 in Wnt5a-treated M0 macrophages. e ELISA analysis for IL10 secretion level in M0 macrophages treated with Wnt5a. f, g Flow cytometry analysis of M2 cells ratio in Wnt5a-stimulated M0 macrophages with or without IL-10 antibody or IgG or recombinant IL10 protein. h Confocal immunofluorescence analysis showed the co-localization expression of Wnt5a, CD163 and IL-10 in CRC sample. Bar = 25 μm. All experiments were performed independently at least three times. Statistical analysis was conducted using one-way ANOVA. Error bars, SEM. ns, not significant. *P < 0.05. **P < 0.01. ***P < 0.001
Fig. 4Wnt5a up-regulates IL-10 expression by activating CaKMII-ERK1/2-STAT3 pathway. a Western blot analysis of p-ERK1/2, p-STAT3 and p-NF-κB p65 expression in M0 macrophages with or without Wnt5a. b Immunofluorescence staining for ERK1/2 and STAT3 in M0 macrophages with or without Wnt5a. Bar = 25 μm. c Western blot analysis of IL-10, p-ERK1/2 and p-STAT3 expression in Wnt5a-treated M0 macrophages with or without U0126 or S3I-201. d Flow cytometry analysis of Wnt5a-treated M0 macrophages with or without U0126 or S3I-201. Error bars, SEM. e ELISA analysis of IL-10 secretion level in Wnt5a-treated M0 macrophages with or without U0126 or S3I-201. Error bars, SEM. f Western blot analysis of Wnt5a-treated M0 macrophages with or without CK59 or U0126 or S3I-201. g ELISA analysis of IL-10 secretion level in Wnt5a-treated M0 macrophages with or without CK59. Error bars, SEM. h Flow cytometry analysis of Wnt5a-treated M0 macrophages with or without CK59. Error bars, SEM. All experiments were performed independently at least three times. Statistical analysis was conducted using one-way ANOVA. ***P < 0.001
Fig. 5Wnt5a indirectly promotes tumor proliferation, migration and invasion through M2 macrophages. a Flow chart of CRC cells co-cultured with M0 macrophages treated with Wnt5a or Wnt5a + IL-10 antibody or Wnt5a + IgG. b, c Representative photographs and quantifications of clone formation assay in HCT116 and DLD-1 cells co-cultured with conditioned M0 macrophages. Bar = 0.5 cm. d, e Transwell migration assay of HCT116 and DLD-1 cells co-cultured with conditioned M0 macrophages. Bar = 200 μm. f, g Transwell invasion assay of HCT116 and DLD-1 cells co-cultured with conditioned M0 macrophages. Bar = 200 μm. All experiments were performed in triplicate. Statistical analysis was conducted using one-way ANOVA. Error bars, SEM. ns, not significant. ***P < 0.001
Fig. 6Wnt5a is crucial for the pro-tumor functions of TAMs. a Western blot analysis of TAMs with or without Box 5. b Western blot analysis of TAMs with or without U0126 or S3I-201. c Western blot analysis of TAMs with or without CK59. d ELISA detected the secretion of IL-10 in TAMs treated with inhibitors. Error bars, SEM. e Flow cytometry analysis of TAMs with or without inhibitors. Error bars, SEM. f, g Representative photographs and quantification of clone formation assay in HCT116 and DLD-1 cells co-cultured with M0 macrophages and TAMs transfected with sh-Wnt5a or sh-NC. Bar = 0.5 cm. Error bars, SEM. h, i Transwell migration assay of HCT116 and DLD-1 cells co-cultured with conditioned macrophages. Error bars, SEM. Bar = 200 μm. j, k Transwell invasion assay of HCT116 and DLD-1 cells co-cultured with conditioned macrophages. Error bars, SEM. Bar = 200 μm. All experiments were performed in triplicate. Statistical analysis was conducted using one-way ANOVA. *P < 0.05. **P < 0.01. ***P < 0.001
Fig. 7Silencing Wnt5a suppresses M2-like TAM-mediated tumor growth and metastasis in vivo. a-c The morphological characteristics of tumor xenograft, tumor size and tumor weight in the HCT116 alone, HCT116 + sh-NC TAM and HCT116 + sh-Wnt5a TAM groups. Error bars, SEM. d Relative mRNA expression of Wnt5a, CD163 and IL-10 of tumors in different groups. Error bars, SEM. e IHC analyzed the expression of Wnt5a, CD163 and IL-10 protein of tumors in different groups. Bar = 50 μm. f Western blot analysis of Wnt5a, IL-10, p-CaMKII, p-ERK1/2, and p-STAT3 expression in different groups. g IHC analyzed Ki67 expression of tumors in different groups. Bar = 50 μm. Error bars, SEM. h Representative CTC images of immunofluorescence. Bar = 20 μm. i Quantification of CTCs captured from the blood of mice. Error bars, SEM. j Representative H&E stained sections of metastatic nodules in liver and lung tissue from mice in the HCT116+ sh-NC TAM group were shown. Bar = 200 μm. k Quantification of mice with metastasis lesions in different groups. Statistical analysis was conducted using one-way ANOVA. *P < 0.05. **P < 0.01. ***P < 0.001